Literature DB >> 34061771

Global epidemiology of acromegaly: a systematic review and meta-analysis.

Salvatore Crisafulli1, Nicoletta Luxi2, Janet Sultana3,4, Andrea Fontana5, Federica Spagnolo6,7, Giuseppe Giuffrida6,7, Francesco Ferraù6,7, Daniele Gianfrilli8, Alessia Cozzolino8, Maria Cristina De Martino9, Federico Gatto10, Francesco Barone-Adesi11,12, Salvatore Cannavò6,7, Gianluca Trifirò2.   

Abstract

OBJECTIVE: To date, no systematic reviews and meta-analysis on the global epidemiology of acromegaly are available in the literature. The aims of this study are to provide a systematic review and a meta-analysis of the global epidemiology of acromegaly and to evaluate the quality of study reporting for the identified studies.
METHODS: MEDLINE, EMBASE and The Cochrane Library databases were searched for studies assessing the epidemiology of acromegaly from inception until 31 January 2020. We included original observational studies written in English, reporting acromegaly prevalence and/or incidence for a well-defined geographic area. Two reviewers independently extracted data and performed quality assessments. Prevalence and incidence pooled estimates were derived by performing a random-effects meta-analysis.
RESULTS: A total of 32 studies were included in the systematic review, and 22 of them were included in the meta-analysis. The pooled prevalence of acromegaly was 5.9 (95% CI: 4.4-7.9) per 100 000 persons, while the incidence rate (IR) was 0.38 (95% CI: 0.32-0.44) cases per 100 000 person-years. For both prevalence and IR, considerable between-study heterogeneity was found (I2 = 99.3 and 86.0%, respectively). The quality of study reporting was rated as the medium for 20 studies and low for 12 studies.
CONCLUSIONS: Although the largest amount of heterogeneity was due to the high precision of the studies' estimates, data source and geographic area could represent relevant study-level factors which could explain about 50% of the total between-study variability. Large-scale high-quality studies on the epidemiology of acromegaly are warranted to help the public health system in making decisions.

Entities:  

Mesh:

Year:  2021        PMID: 34061771     DOI: 10.1530/EJE-21-0216

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  5 in total

1.  Evaluation of acromegaly treatment direct costs with respect to biochemical control and follow-up length.

Authors:  Francesco Cocchiara; Claudia Campana; Federica Nista; Giuliana Corica; Marco Ceraudo; Angelo Milioto; Diego Criminelli Rossi; Gianluigi Zona; Diego Ferone; Federico Gatto
Journal:  Pituitary       Date:  2021-11-10       Impact factor: 4.107

Review 2.  A Comprehensive Review of Four Clinical Practice Guidelines of Acromegaly.

Authors:  Oboseh J Ogedegbe; Asfand Yar Cheema; Muhammad Ali Khan; Syeda Zeenat S Junaid; Jolomi K Erebo; Ewuradjoa Ayirebi-Acquah; Jennifer Okpara; Daramfon Bofah; Jennifer G Okon; Mishaal Munir; Gabriel Alugba; Aaron Ezekiel; Ohikhuare Okun; Tioluwani K Ojo; Eunice O Mejulu; Abdulmalik Jimoh
Journal:  Cureus       Date:  2022-09-03

3.  Editorial: Insights Into Acromegaly Complications.

Authors:  Corin Badiu; Przemyslaw Witek
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-27       Impact factor: 6.055

4.  Development and testing of diagnostic algorithms to identify patients with acromegaly in Southern Italian claims databases.

Authors:  Salvatore Crisafulli; Andrea Fontana; Luca L'Abbate; Valentina Ientile; Daniele Gianfrilli; Alessia Cozzolino; Maria Cristina De Martino; Marta Ragonese; Janet Sultana; Francesco Barone-Adesi; Gianluca Trifirò
Journal:  Sci Rep       Date:  2022-09-23       Impact factor: 4.996

5.  Serum NT-pro-BNP Levels Predict Cardiovascular Events in Acromegaly Patients.

Authors:  Marta Ragonese; Gianluca Di Bella; Federica Spagnolo; Loredana Grasso; Angela Alibrandi; Guiseppe Giuffrida; Mariacarla Moleti; Francesco Ferraù; Salvatore Cannavò
Journal:  Exp Clin Endocrinol Diabetes       Date:  2021-12-23       Impact factor: 2.426

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.